Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss – Reproduction and Fertility
Reproduction and Fertility shared a post on LinkedIn:
“Day 4 of RaFJC – Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss (RPL)
Recurrent pregnancy loss (RPL) (two or more consecutive miscarriages) affects 1–2% of couples worldwide. Up to 50% of cases remain unexplained, with immune maladaptation at the maternal–fetal interface increasingly recognised as a key driver.
Current therapies rely on systemic immunosuppression (corticosteroids, IVIG, TNF inhibitors), which:
- Show inconsistent efficacy
- Carry significant risks
- Are costly and not always accessible
This highlights the urgent need for localised, safer, and cost‑effective therapies.
Mohsen Dashti, Vinnie A., and Mehdi Yousefi propose a placenta‑targeted nanoparticle (NP) system for localized immune cloaking.
Core design:
- PLGA biodegradable matrix
- Lipid‑PEG stealth layer to prolong circulation
- SPIONs for imaging and tracking
- Placental‑homing peptides for site‑specific delivery
Evidence so far:
- Rodent and primate models show placenta‑specific NP delivery is feasible
- NPs can induce anti‑inflammatory cytokines, suppress cytotoxic NK/T cells, and remodel spiral arteries
- Ex vivo human placenta models confirm uptake with minimal fetal exposure
Estimated cost: $0.56–$5.58 per dose, far cheaper than IVIG or biologics. Production is scalable.
In conclusion, placenta‑targeted nanoparticles represent a promising therapy for unexplained RPL, offering localized immune tolerance while avoiding systemic risks.
Read the full article.
Join the discussion in the comments:
- What challenges must be overcome for clinical translation?
- How might localised immune cloaking reshape patient care?
- Which biomarkers should guide future trials?
Explore the Special Collection: Immune Regulation and Inflammatory Mechanisms in Reproductive Health and Disease.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 12, 2026, 16:03New Insights Into Estrogen Receptor Alpha Regulation in the Endometrium – Fertility and Sterility
-
Jan 12, 2026, 15:37From Innovation to Practice: Standards for Embryo Diagnostic Trials – Fertility and Sterility
-
Jan 12, 2026, 14:47HFEA Updates Choose a Fertility Clinic Tool to Improve Success Reporting
-
Jan 12, 2026, 13:14Lucile Ferreux: Prenatal Cadmium Exposure and Its Long-Term Impact on Male Fertility
-
Jan 12, 2026, 13:11This Month’s Fertility and Sterility Unplugged Is Live – Fertility and Sterility
-
Jan 11, 2026, 10:02Hind Hanani: Understanding the Use of Antiphospholipid Syndrome Guidelines Worldwide
-
Jan 11, 2026, 09:58Exploring the Role of Antiphospholipid Antibodies in Severe Preeclampsia – RheumNow
-
Jan 11, 2026, 09:56Adrenal Involvement in Antiphospholipid Syndrome – ARP Rheumatology
-
Jan 11, 2026, 09:52Jamie Agunsday: Understanding Pregnancy-Related Deaths